T-cell factor 1
Gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two major incretin hormones secreted by enteroendocrine K cells and L cells into the circulation after meal ingestion. Nutrients such as glucose, fat, and protein induce incretin secretion. In b cells, GIP and GLP-1 bind to their respective class B G-protein-coupled receptor (GPCR), namely the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), respectively, to potentiate glucose-dependent insulin secretion through cyclic adenosine 3 0 ,5 0 -monophosphate (cAMP) protein kinase A (PKA) and exchange protein (directly activated by cAMP 2 (Epac2) signaling) (Fig. 1) . Systemic incretin receptor-knockout and incretin peptide-knockout mice exhibit impaired glucose tolerance due to a lack of incretin-induced insulin secretion [1] [2] [3] . Thus, the insulinotropic actions of GIP and GLP-1 play an important role in postprandial insulin secretion.
GLP-1 mediates extra-insulinotropic functions in the b cell [4] (Fig. 1) . GLP-1 activates protein kinase B (PKB/ Akt)-which is downstream of phosphoinositide 3-kinase (PI3K)-via epidermal growth factor receptor (EGFR) activation, and increases the expression levels of antiapoptotic gene B-cell lymphoma (Bcl)-2 and Bcl-xL, resulting in a reduction in the proapoptotic gene Bax (Bcl-2-like protein 4) expression in b cells. GLP-1 is associated with b-cell maturation and differentiation through the transcriptional factor pancreatic duodenal homeobox 1 (PDX-1), which is increased by the PKA-cAMP response element-binding protein (CREB) pathway. In addition, GLP-1 signaling reduces endoplasmic reticulum (ER) stress by PKB/Akt and CREB activation. Thus, GLP-1 plays an important role in b-cell proliferation and protection from b-cell apoptosis, resulting in the preservation of b-cell mass.
GIP also has anti-apoptotic functions that are mostly mediated by the activation of CREB and the suppression of p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) [5, 6] . In addition, GIP also protects b cells from ER stress [7] . However, the importance of GIPR in b-cell survival remains relatively unclear. Campbell et al. generated b-cell-specific GIPR-knockout (GIPR -/-bCell ) mice using floxed GIPR and mouse insulin promotor-tamoxifen inducible Cre (MIP-CreERT) mice, and showed the role of GIPR in insulin secretion and b-cell survival in vivo [8] . GIPR -/-bCell mice exhibited similar levels of insulin secretion in response to glucose compared to the MIP-CreERT control mice. However, streptozotocin (STZ)-induced apoptotic b cells were increased in GIPR -/-bCell mice compared to MIP-CreERT mice. Transcription factor 7-like 2 (TCF7L2) is a member of the TCF family that regulates b-cell function and survival [9] . TCF7L2 levels are reported to be negatively correlated with GIPR and GLP-1R expression in human b cells [10] . Campbell et al. investigated the mRNA expression of TCF family members such as TCF7L1, TCF7L2, TCF4, and TCF7, and showed that only TCF7 mRNA expression is suppressed in islets of GIPR -/-bCell mice. The T-cell factor 1 (TCF1) protein encoded by TCF7 is a transcriptional activator which plays an important role in lymphocyte differentiation in T cells [11] , but its functional role in b cells has not been reported. The authors of [11] were able to show that the TCF1 protein may be involved in b-cell survival and that GIPR signaling may be one of the key mediators (Fig. 1) . TCF7 was expressed in b cells, and GIP directly induced TCF7 mRNA expression through cAMP and extracellular signal-regulated kinase (ERK) signaling in rat pancreatic b-cell line INS-1. In addition, TCF7-knockout (TCF7 -/-) mice were found to have lower insulin secretion in response to glucose ingestion, which resulted in postprandial hyperglycemia. Finally, GIP reduced STZ-induced TUNEL-positive cells in the islets of wild-type mice, but not in the islets of TCF7 -/-mice. Accordingly, it is likely that TCF1 plays an important role in b-cell survival through GIPR signaling. GIPR-TCF1 signaling may have potential as a therapeutic target in the treatment of b-cell mass loss under diabetic conditions. 
